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A B S T R A C T
Background
Opioid drugs, including fentanyl, are commonly used to treat neuropathic pain, and are considered effective by some professionals.
Most reviews have examined all opioids together. This review sought evidence specifically for fentanyl, at any dose, and by any route
of administration. Other opioids are considered in separate reviews.
Objectives
To assess the analgesic efficacy of fentanyl for chronic neuropathic pain in adults, and the adverse events associated with its use in
clinical trials.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase from inception to June 2016,
together with the reference lists of retrieved articles, and two online study registries.
Selection criteria
We included randomised, double-blind studies of two weeks’ duration or longer, comparing fentanyl (in any dose, administered by any
route, and in any formulation) with placebo or another active treatment in chronic neuropathic pain.
Data collection and analysis
Two review authors independently searched for studies, extracted efficacy and adverse event data, and examined issues of study quality
and potential bias. We did not carry out any pooled analyses. We assessed the quality of the evidence using GRADE.
Main results
Only one study met our inclusion criteria. Participants were men and women (mean age 67 years), with postherpetic neuralgia, complex
regional pain syndrome, or chronic postoperative pain. They were experiencing inadequate relief from non-opioid analgesics, and had
not previously taken opioids for their neuropathic pain. The study used an enriched enrolment randomised withdrawal design. It was
adequately blinded, but we judged it at unclear risk of bias for other criteria.
Transdermal fentanyl (one-day fentanyl patch) was titrated over 10 to 29 days to establish the maximum tolerated and effective dose
(12.5 to 50 µg/h). Participants who achieved a prespecified good level of pain relief with a stable dose of fentanyl, without excessive
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use of rescue medication or intolerable adverse events (’responders’), were randomised to continue with fentanyl or switch to placebo
for 12 weeks, under double-blind conditions. Our prespecified primary outcomes were not appropriate for this study design, but the
measures reported do give an indication of the efficacy of fentanyl in this condition.
In the titration phase, 1 in 3 participants withdrew because of adverse events or inadequate pain relief, and almost 90% experienced
adverse events. Of 258 participants who underwent open-label titration, 163 were ’responders’ and entered the randomised withdrawal
phase. The number of participants completing the study (and therefore continuing on treatment) without an increase of pain by
more than 15/100 was 47/84 (56%) with fentanyl and 28/79 (35%) with placebo. Because only 63% responded sufficiently to enter
the randomised withdrawal phase, this implies that only a maximum of 35% of participants entering the study would have had
useful pain relief and tolerability with transdermal fentanyl, compared with 22% with placebo. Almost 60% of participants taking
fentanyl were ’satisfied’ and ’very satisfied’ with their treatment at the end of the study, compared with about 40% with placebo. This
outcome approximates to our primary outcome of moderate benefit using the Patient Global Impression of Change scale, but the group
was enriched for responders and the method of analysis was not clear. The most common adverse events were constipation, nausea,
somnolence, and dizziness.
There was no information about other types of neuropathic pain, other routes of administration, or comparisons with other treatments.
We downgraded the quality of the evidence to very low because there was only one study, with few participants and events, and there
was no information about how data from people who withdrew were analysed.
Authors’ conclusions
There is insufficient evidence to support or refute the suggestion that fentanyl works in any neuropathic pain condition.
P L A I N L A N G U A G E S U M M A R Y
Fentanyl for neuropathic pain in adults
Bottom line
There is no good evidence to support or refute the suggestion that fentanyl works in any neuropathic pain condition.
Background
Neuropathic pain is pain coming from a damaged nervous system. It is different from pain messages that are carried along healthy nerves
from damaged tissue (e.g. from a fall or cut, or an arthritic knee). Neuropathic pain is often treated by different medicines (drugs) from
those used for pain from damaged tissue, which we often think of as painkillers. There are different types of neuropathic pain, with
different causes. Some medicines that are used to treat depression or epilepsy can be very effective in some people with neuropathic
pain. Sometimes opioid painkillers are used to treat neuropathic pain.
Opioid painkillers are drugs such as morphine. Morphine is derived from plants, but many opioids are also made by chemical synthesis
rather than being extracted from plants. Fentanyl is one of these synthetic opioids. It is available in numerous countries for use as a
painkiller and, when used to treat chronic pain, is usually given through an adhesive patch, so it is taken into the body through the
skin.
Study characteristics
In January 2016 we searched for clinical trials where fentanyl was used to treat neuropathic pain in adults. We found one small study that
did this and met our requirements for the review. The study had a complicated design. Study participants first received fentanyl (as one-
day skin patches) for one month. Those who responded to therapy (achieved a predetermined level of pain relief ) were then randomly
allocated to continue receiving fentanyl or placebo for 12 weeks. The participants had one of three different types of neuropathic pain
and had not taken opioids before. There were only 163 people in the 12-week comparison with placebo.
Key results
The study found that more people taking fentanyl had pain relief than those taking placebo. About 1 in 7 participants stopped taking
fentanyl because of side effects, and 1 in 5 did not get a good level of pain relief in the first part of the study. Almost half of those
who continued into the second part of the study also stopped. The most common side effects were constipation, nausea (feeling sick),
somnolence (feeling sleepy), and dizziness. These are typical side effects with opioids such as fentanyl. There was so little information
2Fentanyl for neuropathic pain in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
from this single study that we concluded there was no convincing evidence to support or reject a meaningful benefit for fentanyl over
placebo.
Quality of the evidence
We rated the quality of the evidence as very low because there was only one study, with few participants and events, and an unusual
design. Very-low-quality evidence means that we are very uncertain about the results.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Transdermal fentanyl compared with placebo for neuropathic pain
Patient or population: Adults with chronic neuropathic pain
Settings: Community
Intervention: Fentanyl 1-day adhesive patch 12.5 to 50 µg/ h
Comparison: Placebo patch
Outcomes Probable outcome with
intervention
Probable outcome with
comparator
RR
(95% CI)
No of studies, participants Quality of the evidence
(GRADE)
Comments
Moderate benef it :
at least 30% reduct ion
in pain, or
PGIC much or very
much improved
Pain treatment: sat is-
f ied, very sat isf ied
49/ 84
Pain treatment: sat is-
f ied, very sat isf ied
32/ 79
Not
calculated
1 study, 163 part icipants,
81 events
Very low Downgraded three t imes:
single study, few part ici-
pants and events, approxi-
mates to prespecif ied out-
come, imputat ion for with-
drawals not specif ied, un-
usual m ix of pain condi-
t ions
Substant ial benef it :
at least 50% reduct ion
in pain, or
PGIC much improved
No data No data - - - -
Lack of ef f icacy with-
drawal in randomised
double-blind phase
19/ 84 39/ 79 Not
calculated
1 study, 163 part icipants,
81 events
Very low Downgraded three t imes:
single study, few part ici-
pants and events
Adverse event with-
drawal in randomised
double-blind phase
14/ 84 4/ 79 Not
calculated
1 study, 163 part icipants,
81 events
Very low Downgraded three t imes:
single study, few part ici-
pants and events
4
F
e
n
ta
n
y
l
fo
r
n
e
u
ro
p
a
th
ic
p
a
in
in
a
d
u
lts
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Serious adverse events 13/ 258 during t it rat ion
phase
8/ 84 in randomised
double-blind phase
4/ 79 in randomised
double-blind phase
Not
calculated
Titrat ion: 1 study, 258 par-
t icipants, 13 events
Randomised double-blind
phase: 1 study, 163 part ic-
ipants, 12 events
Very low Downgraded three t imes:
single study, few part ici-
pants and events
Deaths None None - 1 study, 258 part icipants,
0 events
Very low Downgraded three t imes:
est imated incidence not
more f requent than 1 in 86
1
CI: Conf idence interval; PGIC: Patient Global Impression of Change; RR: Risk Ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Eypasch E, Lefering R, Kum CK, Troidl H. Probability of adverse events that have not yet occurred: a stat ist ical reminder.
BMJ 1995;311(7005):619-20.
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B A C K G R O U N D
This review is based on a template for reviews of drugs used to
relieve neuropathic pain. The aim is for all reviews to use the
same methods, based on new criteria for what constitutes reliable
evidence in chronic pain (Moore 2010a; Appendix 1).
Description of the condition
The 2011 International Association for the Study of Pain defi-
nition of neuropathic pain is “pain caused by a lesion or disease
of the somatosensory system” (Jensen 2011), and is based on a
definition agreed at an earlier consensus meeting (Treede 2008).
Neuropathic pain may be caused by nerve damage, but is often
followed by changes in the central nervous system (Moisset 2007).
The origin of neuropathic pain is complex (Baron 2010; Baron
2012; Tracey 2011; von Hehn 2012), and neuropathic pain fea-
tures can be found in people with joint pain (Soni 2013).
Many people with neuropathic pain conditions are significantly
disabledwithmoderate or severe pain formany years. Chronic pain
conditions comprised 5 of the 11 top-ranking conditions for years
lived with disability in 2010 (Vos 2012), and are responsible for
considerable loss of quality of life and employment, and increased
healthcare costs (Moore 2014a).
Neuropathic pain is usually divided according to the cause of
nerve injury. Theremay bemany causes, but some common causes
of neuropathic pain include diabetes (painful diabetic neuropa-
thy (PDN)), shingles (postherpetic neuralgia (PHN)), amputation
(stump and phantom limb pain), neuropathic pain after surgery
or trauma, stroke or spinal cord injury, trigeminal neuralgia, and
HIV infection. Sometimes the cause is unknown.
In systematic reviews, the overall prevalence of neuropathic pain
in the general population is reported to be between 7% and 10%
(van Hecke 2014), and about 7% in a systematic review of stud-
ies published since 2000 (Moore 2014a). In individual countries,
prevalence rates have been reported as 3.3% in Austria (Gustorff
2008), 6.9% in France (Bouhassira 2008), and up to 8% in the
UK (Torrance 2006). Some forms of neuropathic pain, such as
PDN and postsurgical chronic pain (which is often neuropathic
in origin), are increasing in prevelance (Hall 2008).
Estimates of incidence vary between individual studies for partic-
ular origins of neuropathic pain, often because of small numbers
of cases. In primary care in the UK, between 2002 and 2005,
the incidences (per 100,000 person-years’ observation) were 28
(95% confidence interval (CI) 27 to 30) for PHN, 27 (26 to 29)
for trigeminal neuralgia, 0.8 (0.6 to 1.1) for phantom limb pain,
and 21 (20 to 22) for PDN (Hall 2008). Others have estimated
an incidence of 4 in 100,000 per year (Katusic 1991; Rappaport
1994) for trigeminal neuralgia, and of 12.6 per 100,000 person-
years for trigeminal neuralgia and 3.9 per 100,000 person-years
for PHN in a study of facial pain in the Netherlands (Koopman
2009). One systematic review of chronic pain demonstrated that
some neuropathic pain conditions, such as PDN, can be more
common than other neuropathic pain conditions, with prevalence
rates up to 400 per 100,000 person-years (McQuay 2007).
Neuropathic pain is difficult to treat effectively, with only a mi-
nority of people experiencing a clinically relevant benefit from
any one intervention. A multidisciplinary approach is now advo-
cated, combining pharmacological interventions with physical or
cognitive (or both) interventions. Conventional analgesics such
as paracetamol and nonsteroidal anti-inflammatory drugs are not
thought to be effective, but are frequently used (Di Franco 2010;
Vo 2009). Some people may derive some benefit from a topical
lidocaine patch or low-concentration topical capsaicin, although
evidence about benefits is uncertain (Derry 2012; Derry 2014).
High-concentration topical capsaicin may benefit some people
with PHN (Derry 2013).
Treatment is often by so-called ’unconventional analgesics’, such as
antidepressants (duloxetine and amitriptyline; Lunn 2014; Moore
2012a; Sultan 2008), or antiepileptics (gabapentin or pregabalin;
Moore 2009; Moore 2014b; Wiffen 2013). The proportion of
people who achieve worthwhile pain relief (typically at least 50%
pain intensity reduction; Moore 2013a) is small, generally only
10% to 25% more than with placebo, with numbers needed to
treat for an additional beneficial outcome (NNT) usually between
4 and 10 (Kalso 2013; Moore 2013b). Neuropathic pain is not
particularly different from other chronic pain conditions in that
only a small proportion of trial participants have a good response
to treatment (Moore 2013b).
One overview of treatment guidelines pointed out some general
similarities between recommendations, but guidelines are not al-
ways consistent with one another (O’Connor 2009). The cur-
rent National Institute for Health and Care Excellence (NICE)
guidance suggests offering a choice of amitriptyline, duloxetine,
gabapentin, or pregabalin as initial treatment for neuropathic pain
(with the exception of trigeminal neuralgia), with switching if the
first, second, or third drugs tried are not effective or not tolerated
(NICE 2013).
Description of the intervention
Fentanyl was first synthesised in the 1950s and was found to be
significantly more potent than commonly used opioids, such as
morphine. It was initially used for intravenous anaesthesia and
analgesia in the 1960s and became a mainstay of intraoperative
and perioperative analgesia and both conscious and deep sedation
in the in-hospital setting. Peak analgesic effects of intravenous fen-
tanyl last for 30 to 60 minutes, but onset of analgesia is rapid.
Fentanyl is approximately 80 to 100 times more potent than mor-
phine, is highly lipophilic, and binds strongly to plasma proteins
(Trescot 2008). Fentanyl is associated with possible hypoxaemia
(low oxygen levels in the blood) after surgery (McQuay 1979).
Fentanyl undergoes extensive metabolism in the liver, and is sub-
ject to first-pass metabolism in the liver and possibly small intes-
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tine, though hepatic extraction from blood may be more compli-
cated (Bullingham 1984). Various formulations of fentanyl have
been studied, including a rapid transmucosal formulation for buc-
cal absorption or intranasal sprays for acute breakthrough pain,
and transdermal formulations for chronic pain (Lötsch 2013;
Nelson 2009). The transdermal formulation has a lag time of 6 to
12 hours to onset of action after application, and typically reaches
steady state in three to six days. When a patch is removed, a sub-
cutaneous reservoir remains, and drug clearance may take up to
24 hours.
Fentanyl patches are available as generic formulations, and brand
names include Fentalis®, Matrifen®, Mezolar®, Osmanil®, Tilo-
fyl®, Victanyl®, Durogesic®, and DTrans® . They are available
as 12, 25, 50, 75, and 100 µg/h transdermal patches. The 25,
50, 75, and 100 µg/h patches were first licensed in 1994, and
a 12 µg patch followed in 2005. Transdermal fentanyl provides
’rate controlled’ drug delivery over 72 hours, although shorter and
longer delivery periods are under development. A 24-hour patch
has been licensed for some pain conditions in Japan. Surface area
exposed, skin permeability, and local blood flowdetermine absorp-
tion (Heiskanen 2009). Absorption was impaired in 10 cachectic
(weak and underweight) compared with 10 normal weight cancer
patients, (Heiskanen 2009). The ’reservoir patch’ is being phased
out and replaced with a matrix design, as it was likely to leak if
damaged or cut. Trials have demonstrated no difference in pain
intensity reduction or overall adverse effects between the reservoir
and matrix patches. Satisfaction was improved, and wearability,
adhesion, and comfort were improved with the matrix patches
(Cachia 2011).
Fentanyl patches have been suggested to have some benefits
over more traditional opioids such as oral morphine. There is a
favourable safety profile in people with renal insufficiency, as this
does not affect fentanyl elimination, while renal insufficiency or
failure cause a build-up of active metabolites of opioids such as
morphine. Fentanyl is also considered to cause less constipation
than morphine. However, fentanyl patches are not generally rec-
ommended in clinical practice for people who are opioid naïve.
Moreover, exposure to heat through fever, sunbathing, hot showers
or baths, and warm weather can cause more fentanyl to be released
into the skin and cause serious, or even fatal, adverse events.
How the intervention might work
Opioids such as fentanyl bind to specific opioid receptors in the
nervous system and other tissues; there are three principal classes
of receptors (mu, kappa, and delta) though others have been sug-
gested, and subtypes of receptors are considered to exist. Binding
of opioid agonists such as fentanyl to receptors brings about com-
plex cellular changes, the outcomes of which include decreased
perception of pain, decreased reaction to pain, and increased pain
tolerance. Opioids from plant sources have been used for thou-
sands of years to treat pain.
Why it is important to do this review
One UK survey found that weak and strong opioids were used
frequently for treating neuropathic pain (Hall 2013). Fentanyl
patches can be useful in people who cannot tolerate oral opioids.
Titrating the dose of fentanyl patches can be difficult and it is prob-
ably better to convert from a dose of morphine or other oral opioid
that is effective but not tolerated. Since the early 2000s, a marked
increase in prescribing of opioids for non-cancer pain in general,
despite a relatively modest evidence base, has in some countries
led to widespread diversion with consequent abuse, misuse, and
mortality (Franklin 2014; Weisberg 2014; Zin 2014). There were
1.2 million prescriptions for fentanyl in primary care in England
in 2014 at a cost of almost GBP57 million (PCA 2015) and the
amount of fentanyl prescribed has been rising substantially (Zin
2014), although not all this prescribing will be for neuropathic
pain.
Concurrently, suspicion has arisen that opioid-induced hyperal-
gesia, together with tolerance to the analgesic effects of opioids,
may in reality result in a lesser degree of benefit for opioids in
neuropathic pain than previously assumed.
The standards used to assess evidence in chronic pain trials have
evolved substantially in recent years, with particular attention be-
ing paid to trial duration, withdrawals, and statistical imputation
following withdrawal, all of which can substantially alter estimates
of efficacy. The most important change is the move from using
mean pain scores, or mean change in pain scores, to the number of
people who have a large decrease in pain (by at least 50%) and who
continue in treatment, ideally in trials of 8 to 12 weeks’ duration
or longer. A pain intensity reduction of 50% or more correlates
with improvements in comorbid symptoms, function, and quality
of life. These standards are set out in the Cochrane Pain, Palliative
and Supportive Care Group (PaPaS) Author and Referee Guidance
for pain studies (PaPaS 2012).
This Cochrane review assessed evidence using methods that make
both statistical and clinical sense, and used developing criteria for
what constitutes reliable evidence in chronic pain (Moore 2010a).
To be included, trials had to meet a minimum of reporting qual-
ity (blinding, randomisation), validity (duration, dose and timing,
diagnosis, outcomes, etc.), and size (ideally at least 500 partici-
pants in a comparison in which the NNT is 4 or above; Moore
1998). This approach sets high standards for the demonstration of
efficacy and marks a departure from how reviews were conducted
previously.
Taking this newer, more rigorous approach is particularly impor-
tant for opioids in chronic non-cancer pain. Opioids in clinical
trials in non-cancer pain are associated with very high withdrawal
rates of up to 60% over about 12 weeks (Moore 2010b). Many
withdrawals occur within the first few weeks, when participants
experience pain relief but cannot tolerate the drug. The common
practice of using the last observed results carried forward to the
end of the trial many weeks later (last observation carried forward
(LOCF)) can, therefore, produce results based largely on people
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who are no longer in the trial, and who in the real world could
not achieve pain relief because they could not take the tablets. The
newer standards, outlined in Appendix 1, would not allow this and
can produce very different results. For example, one large analysis
of pooled data from trials in osteoarthritis and chronic low back
pain conducted over about 12 weeks judged oxycodone effective,
but an analysis of the same data using the new clinically mean-
ingful standards showed it to be significantly worse than placebo
(Lange 2010).
One previous Cochrane review demonstrated the limitations of
our knowledge about opioids in neuropathic pain except in short
duration studies of 24 hours or less (McNicol 2013). These limi-
tations were confirmed by reviews specific to buprenorphine and
oxycodone (Gaskell 2014; Wiffen 2015). A review specific to fen-
tanyl is timely.
O B J E C T I V E S
To assess the analgesic efficacy of fentanyl for chronic neuropathic
pain in adults, and the adverse events associated with its use in
clinical trials.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials with double-blind as-
sessment of participant outcomes following two weeks or more
of treatment, although the emphasis of the review was on studies
with a duration of eight weeks or longer. We required full jour-
nal publication, with the exception of online clinical trial results
summaries of otherwise unpublished clinical trials and abstracts
with sufficient data for analysis. We did not include short abstracts
(usually meeting reports). We excluded studies that were non-ran-
domised, studies of experimental pain, case reports, and clinical
observations.
Types of participants
We included studies involving adults aged 18 years and above with
one or more chronic neuropathic pain condition including (but
not limited to):
1. cancer-related neuropathy;
2. central neuropathic pain;
3. complex regional pain syndrome (CRPS) Type II;
4. human immunodeficiency virus (HIV) neuropathy;
5. painful diabetic neuropathy (PDN);
6. phantom limb pain;
7. postherpetic neuralgia (PHN);
8. postoperative or traumatic neuropathic pain;
9. spinal cord injury;
10. trigeminal neuralgia.
Where studies included participants with more than one type of
neuropathic pain, we planned to analyse results according to the
primary condition.
Types of interventions
Fentanyl at any dose, by any route, administered for the relief
of neuropathic pain and compared with placebo or any active
comparator.
Types of outcome measures
We anticipated that studies would use a variety of outcome mea-
sures, with most studies using standard subjective scales (numer-
ical rating scale (NRS) or visual analogue scale (VAS)) for pain
intensity (where higher numbers indicate more pain) or pain relief
(where higher numbers indicate more relief ), or both. We were
particularly interested in Initiative onMethods,Measurement, and
Pain Assessment in Clinical Trials (IMMPACT) definitions for
moderate and substantial benefit in chronic pain studies (Dworkin
2008). These are defined as:
1. at least 30% pain relief over baseline (moderate benefit);
2. at least 50% pain relief over baseline (substantial benefit);
3. much or very much improved on Patient Global Impression
of Change scale (PGIC; moderate benefit); and
4. very much improved on PGIC (substantial benefit).
These outcomes are different from those used in most earlier re-
views, concentrating as they do on dichotomous outcomes where
pain responses do not follow a normal (Gaussian) distribution.
People with chronic pain desire high levels of pain relief, ideally
more than 50% pain intensity reduction, and ideally having no
worse than mild pain (Moore 2013a; O’Brien 2010).
We have included a ’Summary of findings’ table as set out in the
PaPaS author guide (PaPaS 2012), to include outcomes of at least
30% and at least 50% pain intensity reduction, much or very
much improvement on PGIC, withdrawals due to adverse events,
serious adverse events, and death. We used the GRADE approach
to assess the quality of evidence related to each of the key outcomes
listed below (Chapter 12, Higgins 2011), as appropriate.
Primary outcomes
1. Participant-reported pain relief of 30% or greater
2. Participant-reported pain relief of 50% or greater
3. PGIC much or very much improved
4. PGIC very much improved
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Secondary outcomes
1. Any pain-related outcome indicating some improvement
2. Withdrawals due to lack of efficacy, adverse events, and for
any cause
3. Participants experiencing any adverse event
4. Participants experiencing any serious adverse event. Serious
adverse events typically include any untoward medical
occurrence or effect that at any dose results in death, is life-
threatening, requires hospitalisation or prolongation of existing
hospitalisation, results in persistent or significant disability or
incapacity, is a congenital anomaly or birth defect, is an
’important medical event’ that may jeopardise the person, or may
require an intervention to prevent one of the above
characteristics or consequences
5. Specific adverse events, particularly somnolence and
dizziness
Search methods for identification of studies
Electronic searches
We searched the following databases, without language restric-
tions.
1. Cochrane Central Register of Controlled Trials
(CENTRAL, via the Cochrane Register of Studies Online
database (CRSO)) to 14 June 2016.
2. MEDLINE (via Ovid) from 1946 to 14 June 2016.
3. Embase (via Ovid) from 1974 to 14 June 2016.
The search strategies for CENTRAL,MEDLINE, and Embase are
listed in Appendix 2, Appendix 3, and Appendix 4, respectively.
Searching other resources
We reviewed the bibliographies of relevant studies and review ar-
ticles, and searched two clinical trial registries, (ClinicalTrials.gov
(ClinicalTrials.gov) and the World Health Organization Interna-
tional Clinical Trials Registry Platform (ICTRP) (apps.who.int/
trialsearch/)), to identify additional published or unpublished
data. We contacted Janssen-Cilag Ltd who were able to clarify the
publication status of the included study shortly before full publi-
cation. We did not contact investigators or other study sponsors.
Data collection and analysis
We planned to perform separate analyses according to particu-
lar neuropathic pain conditions, combining different neuropathic
pain conditions in analyses for exploratory purposes only.
Selection of studies
We determined eligibility by reading the abstract of each study
identified by the search. We eliminated studies that clearly did
not satisfy the inclusion criteria, and obtained full copies of the
remaining studies. Two review authorsmade the decisions, reading
these studies independently and reaching agreement by discussion.
We did not anonymise the studies in any way before assessment.
We have included a PRISMA flow chart (Figure 1).
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Figure 1. Study flow diagram.
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Data extraction and management
Two review authors extracted data independently using a standard
form and checked for agreement before entry into Review Man-
ager 5 (RevMan 2014) or any other analysis tool. We included
information about the pain condition and number of participants
treated, drug and dosing regimen, control intervention, study de-
sign, study duration and follow up, analgesic outcome measures
and results, withdrawals, and adverse events (participants experi-
encing any adverse event or serious adverse event).
Assessment of risk of bias in included studies
We used theOxfordQuality Score as the basis for inclusion (Jadad
1996), limiting inclusion to studies that were randomised and
double-blind as a minimum.
Two review authors independently assessed the risk of bias for
each study, using the criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Chapter 8, Higgins 2011),
and adapted from those used by the Cochrane Pregnancy and
Childbirth Group, with any disagreements resolved by discussion.
We assessed the following for each study.
1. Random sequence generation (checking for possible
selection bias). We assessed the method used to generate the
allocation sequence as: low risk of bias (any truly random
process, random number table, computer random number
generator); unclear risk of bias (when the method used to
generate the sequence is not clearly stated). We excluded studies
at a high risk of bias that used a non-random process (odd or
even date of birth, hospital or clinic record number).
2. Allocation concealment (checking for possible selection
bias). The method used to conceal allocation to interventions
prior to assignment determines whether intervention allocation
could have been foreseen in advance of, or during, recruitment,
or changed after assignment. We assessed the methods as: low
risk of bias (telephone or central randomisation, consecutively
numbered, sealed, opaque envelopes); unclear risk of bias (when
method was not clearly stated). We excluded studies that did not
conceal allocation and were, therefore, at a high risk of bias
(open list).
3. Blinding of outcome assessment (checking for possible
detection bias). We planned to assess the methods used to blind
study participants and outcome assessors from knowledge of
which intervention a participant received. We assessed the
methods as: low risk of bias (study stated that it was blinded and
described the method used to achieve blinding, identical tablets,
matched in appearance and smell); unclear risk of bias (study
stated that it was blinded but did not provide an adequate
description of how it was achieved). We excluded studies at a
high risk of bias that were not double-blind.
4. Incomplete outcome data (checking for possible attrition
bias due to the amount, nature, and handling of incomplete
outcome data). We assessed the methods used to deal with
incomplete data as: low risk of bias (fewer than 10% of
participants did not complete the study, or used ’baseline
observation carried forward’ analysis (BOCF), or both); unclear
risk of bias (used LOCF analysis); or high risk of bias (used
’completer’ analysis).
5. Size of study (checking for possible biases confounded by
small size). We assessed studies as being at low risk of bias (200
participants or more per treatment arm); unclear risk of bias (50
to 199 participants per treatment arm); or high risk of bias
(fewer than 50 participants per treatment arm).
Measures of treatment effect
We planned to calculate NNTs as the reciprocal of the absolute
risk reduction (McQuay 1998). For unwanted effects, the NNT
becomes the number needed to treat for an additional harm-
ful outcome (NNH) and is calculated in the same manner. We
planned to use dichotomous data to calculate risk ratios (RRs) with
95% confidence intervals (CIs) using a fixed-effect model unless
we found significant statistical heterogeneity (see Assessment of
heterogeneity). We planned not to use continuous data in analy-
ses, and intended to extract and use continuous data, which prob-
ably reflect efficacy and utility poorly, only if useful for illustrative
purposes.
Unit of analysis issues
We accepted randomisation to the individual participant only.
We planned to split the control treatment arm between active
treatment arms in a single study if the active treatment arms were
not combined for analysis.
Dealing with missing data
We planned to use intention-to-treat (ITT) analysis where the
ITT population consisted of participants who were randomised,
took at least one dose of the assigned study medication, and pro-
vided at least one post-baseline assessment. We would assign zero
improvement to missing participants wherever possible.
Assessment of heterogeneity
Weplanned to deal with clinical heterogeneity by combining stud-
ies that examined similar conditions, and to assess statistical het-
erogeneity visually (L’Abbé 1987) and with the use of the I2 statis-
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tic. When the I2 value was greater than 50%, we would consider
possible reasons for this.
Assessment of reporting biases
The aim of this reviewwas to use dichotomous outcomes of known
utility and of value to patients with pain (Hoffman 2010; Moore
2010c; Moore 2010d; Moore 2010e; Moore 2013a). The review
would not depend onwhat the authors of the original studies chose
to report or not, though clearly difficulties would arise in studies
that did not report any dichotomous results.
We planned to assess publication bias using a method designed to
detect the amount of unpublished data with a null effect required
to make any result clinically irrelevant (usually taken to mean an
NNT of 10 or higher; Moore 2008).
Data synthesis
We planned to use a fixed-effect model for meta-analysis. We
would have used a random-effects model for meta-analysis if there
was significant clinical heterogeneity and it was considered appro-
priate to combine studies. We planned to analyse data for each
painful condition separately.
Quality of the evidence
We used the GRADE system to assess the quality of the evidence
related to the key outcomes listed in Types of outcome measures,
as appropriate (Appendix 5; Chapter 12.2, Higgins 2011). Two
review authors independently rated the quality of evidence for
each outcome.
We paid particular attention to:
1. inconsistency, where point estimates vary widely across
studies, or CIs of studies show minimal or no overlap (Guyatt
2011);
2. potential for publication bias, based on the amount of
unpublished data required to make the result clinically irrelevant
(Moore 2008).
In addition, there may be circumstances where the overall rating
for a particular outcome needs to be adjusted as recommended
by GRADE guidelines (Guyatt 2013a). For example, if there are
so few data that the results are highly susceptible to the random
play of chance, or if a study used LOCF imputation in circum-
stances where there are substantial differences in adverse event
withdrawals, onewould have no confidence in the result andwould
need to downgrade the quality of the evidence by three levels to
very low quality. In circumstances where no data were reported
for an outcome, we would report the level of evidence as very low
quality (Guyatt 2013b).
’Summary of findings’ table
We have included a ’Summary of findings’ table to present the
main findings in a transparent and simple tabular format. In par-
ticular, we have included key information concerning the quality
of evidence, themagnitude of effect of the interventions examined,
and the sum of available data on the outcomes of ’moderate’ and
’substantial’ benefit, withdrawal due to lack of efficacy, withdrawal
due to adverse events, serious adverse events, and death.
Subgroup analysis and investigation of heterogeneity
We planned all analyses to be according to individual neuropathic
pain conditions, because placebo response rates for the same out-
come can vary between conditions, as can the drug-specific effects
(Moore 2009).
We did not plan subgroup analyses since our experience of pre-
vious reviews indicates that there would be too few data for any
meaningful subgroup analysis (Gaskell 2014; McNicol 2013).
Sensitivity analysis
We planned no sensitivity analysis because the evidence base was
known to be too small to allow reliable analysis. We planned to
examine details of dose-escalation schedules in the unlikely situ-
ation that this could provide some basis for a sensitivity analysis,
but this was not possible.
R E S U L T S
Description of studies
Results of the search
Searches identified 193 potentially relevant records inCENTRAL,
452 in MEDLINE, and 770 in Embase, and two in clinical trial
registries. After deduplication and reading the titles and abstracts
we obtained and read the full texts of five published records and
two clinical trial registry reports. We excluded five studies, and
included one (two reports) (Figure 1).
Included studies
We included one study, identified as a registry report
(NCT01008553) and in a published pooled analysis (Arai 2015).
This study used an enriched enrolment randomised withdrawal
(EERW) design in which 258 participants underwent open-label
titration over 10 to 29 days with fentanyl one-day patches to deter-
mine the maximum tolerated dose. It was not clear whether par-
ticipants stopped or continued with previously inadequate medi-
cation.
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Those who had pain intensity below 45/100 in the last three days
of this open-label titration, an improvement frompre-treatment of
at least 15/100, achieved a stable dosage of fentanyl, and required
fewer than two doses per day of rescue medication, were classified
as ’responders’ (163 participants; 63% of those entering the open
titration period) and were randomised to double-blind treatment
with either the same dose of fentanyl or placebo for 12 weeks. Of
84 receiving fentanyl, 47 completed the 12 weeks, compared with
28/79 receiving placebo (Arai 2015).
Fentanyl was administered as a one-day patch, and all participants
started with fentanyl 12.5 µg/h, increasing to a maximum of 50
µg/h over 10 to 29 days. Morphine hydrochloride was available as
rescue medication (5 mg per fentanyl 12.5 µg/h).
Participants were opioid-naïve and had pain that was not ade-
quately controlled with non-opioid analgesics. They were adults
(mean age 67 years) with PHN (51%), CRPS (type not speci-
fied, 20%), or chronic postoperative pain (for a duration of 12
weeks or more, but no further details given; 29%). There were
approximately equal numbers of men and women. Mean baseline
pain intensity was 74/100 before treatment and 40/100 at the end
of titration. For those entering the double-blind period, baseline
pain was 30/100 in the fentanyl group and 28/100 in the placebo
group.
Excluded studies
We excluded five studies. Three were open-label studies, two of
which were in mixed pain conditions, one was a single-blind
study (ongoing), and one compared fentanyl with fentanyl plus
gabapentin (no appropriate control). See the Characteristics of
excluded studies table.
Risk of bias in included studies
See Figure 2 for a summary of our assessment of the risk of bias
in the included study. Studies with EERW designs are likely to
have additional sources of bias, or may require somewhat different
assessments (Moore 2015), but we have not included those here.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
The study did not report the methods used to generate the ran-
domisation sequence or to conceal allocation (unclear risk of bias).
Blinding
Blinding was achieved by using a placebo patch that was indistin-
guishable from the fentanyl patch. There was a period of down-
titration for the placebo group, which would help to maintain the
blinding (low risk of bias).
Incomplete outcome data
Study didnotmentionhowmissingdatawere handled.The study’s
primary outcome (median time to withdrawal) appears robust,
but other outcomes are unclear.
Other potential sources of bias
We judged the study to be at unclear risk of bias due to its size (84
and 79 participants in treatment arms for the randomised phase).
Effects of interventions
See: Summary of findings for the main comparison
Since we identified only one study for inclusion, we were unable
to carry out any analyses.
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Efficacy
Details of efficacy outcomes are provided in Appendix 6.
Participants with at least 30% or at least 50% pain relief
These outcomes were not reported.
PGIC much or very much improved
The study reported the participants’ assessment of ’treatment sat-
isfaction for pain’ on a five-point scale (very dissatisfied, dissatis-
fied, neither satisfied or dissatisfied, satisfied, very satisfied) after
the double-blind phase.We judged that the categories of ’satisfied’
and ’very satisfied’ approximate to our PGIC outcome of moder-
ate benefit. In the fentanyl group, 49/84 (58%) participants were
either satisfied or very satisfied, and corresponding data in the
placebo group were 32/79 (41%). It is not clear how data from
participants who withdrew due to adverse events were analysed for
this outcome, but some form of imputation must have been used
for participants who withdrew as the numbers are greater than the
number who completed the study.
Other pain-related outcomes
The primary outcome chosen in the study was median time to
withdrawal from the double-blind phase, where withdrawal oc-
curred when there was worsening of pain of 15/100 (mean in-
crease over three consecutive days) from entry into this phase, use
of three or more doses of rescue medication per day for five or
more days, the participant requested it because of a lack of efficacy,
or the participant requested an increase in study drug dosage. The
median time to withdrawal for the placebo group was 45 days, but
could not be estimated for the fentanyl group because fewer than
half the participants withdrew over the 12 weeks; the assumption
must be that the median time to withdrawal was greater than 42
days.
The study did not report the number of participants who remained
’responders’ at the end of the 12-week double-blind treatment
period as a treatment outcome. However, Arai 2015 reports the
number of participants completing the study (and therefore con-
tinuing on treatment) without an increase in pain of more than
15/100. For fentanyl, this was 47/84 (56%) and for placebo it was
28/79 (35%). The implication, then, is that because only 63%
responded sufficiently to enter the randomised withdrawal phase,
only a maximum of 35% of participants entering the study would
have useful pain relief and tolerability with transdermal fentanyl,
compared with 22% with placebo.
The group mean change (increase) in pain intensity from ran-
domisation to the end of the double-blind phase (mean of last
three days) was 0.5/100 (from 30.1 to 29.6) in the fentanyl group,
and 9.6/100 (from 27.5 to 37.1) in the placebo group. This mean
change is unlikely to be of clinical significance, but probablymasks
larger changes in some individuals. It is not clear how data from
participants whowithdrewduring treatment were analysed for this
outcome.
We downgraded the quality of the evidence for efficacy to very low
because there was only one study, with a small number of partici-
pants, low numbers of events, and there was no information about
how participants who withdrew from the study were analysed (see
Summary of findings for the main comparison).
Withdrawals
Details of withdrawals are provided in Appendix 7.
Withdrawals due to lack of efficacy
Following the titration period, 50/258 participants were classified
as non-responders to fentanyl. During the double-blind period,
one participant taking fentanyl withdrew because of perceived
lack of efficacy, and a further 18/84 were withdrawn because they
experienced a greater than 15/100 increase in pain intensity. With
placebo, 4/79 withdrew because of perceived lack of efficacy, and a
further 35/79 were withdrawn because they experienced a greater
than 15/100 increase in pain intensity.
Withdrawals due to adverse events
During titration 39/258 participants withdrew due to adverse
events. During the double-blind period 14/84 participants taking
fentanyl and 4/79 taking placebo withdrew due to adverse events.
Other withdrawals
During titration 12/258 participants withdrew because of physi-
cian (2) or participant (6) decision, participant was determined to
increase dosage (3), and participant was considered not appropri-
ate for the study (1). During the double-blind period 4/84 partici-
pants taking fentanyl withdrew due to physician (1) or participant
(2) decision, and an inability to perform required tests (1), and
8/79 taking placebo withdrew due to physician (2) or participant
(2) decision, and excessive use of rescue medication (4).
We downgraded the quality of the evidence for withdrawals to
very low because there was only one study, with a small number
of participants per treatment arm in the randomised withdrawal
phase, and low numbers of events.
Adverse events
Details of adverse events are provided in Appendix 7.
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Any adverse event
During the titration phase, 231/258 (90%) participants experi-
enced at least one adverse event. During the double-blind phase,
72/84 (86%) and 56/79 (71%) participants experienced at least
one adverse event with fentanyl and placebo, respectively. Gener-
ally, participants experienced fewer adverse events during the dou-
ble-blind period.
Most adverse events were of mild or moderate intensity.
Serious adverse events
During the titration phase, 13/258 participants experienced a seri-
ous adverse event. During the double-blind phase, 8/84 and 4/79
participants experienced a serious adverse event with fentanyl and
placebo, respectively. No serious adverse event occurred in more
than one participant, and no deaths were reported.
Specific adverse events
Constipation (124/258), nausea (103/258), somnolence (118/
258), and dizziness (52/258) were the most common adverse
events reported during the titration period. As would be expected,
the rates of these events were lower in the double-blind period.
Among the 84 participants taking fentanyl in the double-blind
phase, 12 reported constipation, 12 nausea, 12 somnolence, and 6
dizziness, and among 79 taking placebo, 10 reported constipation,
10 nausea, 5 somnolence, and 3 dizziness.
A small number of participants experienced application-site reac-
tions during titration: pruritus (15/258), erythema (8/258), der-
matitis (4/258), rash (3/258). Few participants in either group re-
ported these events during the double-blind period.
We downgraded the quality of the evidence for adverse events to
very low because there was only one study, with a small number
of participants per treatment arm in the randomised withdrawal
phase, and low numbers of events.
D I S C U S S I O N
Summary of main results
We found only one study to include in this review. The study
assessed the efficacy of fentanyl, using the transdermal route of
administration, for the treatment of neuropathic pain in opioid-
naïve participants; 258 participants entered the dose-titration pe-
riod, and 163 ’responders’ entered the double-blind phase. The
results indicated a reduction in pain intensity with open-label fen-
tanyl that was better maintained with fentanyl than placebo in the
randomised, double-blind withdrawal period. However, during
titration, 1 in 3 (101/258) participants withdrew overall, mainly
due to intolerable adverse events (1 in 7; 39/258) or not achieving
a sufficiently good level of pain relief to proceed to the double-
blind phase (1 in 5; 50/258). Of those who did enter the double-
blind phase, only about 1 in 2 (37/84) in the fentanyl group and
2 in 3 (51/79) in the placebo group maintained good pain relief
and were able to tolerate adverse events over 12 weeks.
Taking the pool of participants originally recruited, therefore, after
12 weeks treatment a maximum of about 3 in 10 would have
maintained low pain and continued with the treatment, compared
with 2 in 10 with placebo.
Most (90%) participants experienced adverse events during the
titration phase, and the majority continued to do so in the double-
blind phase, although most participants experienced fewer events.
Most adverse events were of mild or moderate intensity, and the
most common were constipation, nausea, somnolence, and dizzi-
ness, which are typically associated with opioids.
Overall completeness and applicability of
evidence
The amount of evidence we have is small, from a single study.
Although participants had three different types of neuropathic
pain, the study was underpowered to demonstrate a differential re-
sponse. Participants were opioid-naïve at screening, so high num-
bers of adverse events and withdrawals are to be expected; lower
levels might be seen in an unselected or opioid-tolerant popula-
tion. Fentanyl patches are generally not recommended for opioid-
naïve patients.
About half of participants had PHN, 20% had CRPS, and 29%
had chronic postoperative pain at enrolment. The study did not
specify CRPS type II as an inclusion criterion, and provided no
further details about the nature of the surgery leading to postoper-
ative pain. We have no information about the efficacy of fentanyl
in other types of neuropathic pain, such as diabetic neuropathy,
or about routes of administration other than transdermal, or com-
parisons with other active treatments. The particular formulation
used in this study is not commonly used; in most countries a 72-
hour (three-day) patch is available.
As best we know, there is insufficient evidence to support or refute
the use of fentanyl for treating neuropathic pain. This is despite
the fact that a UK survey found that weak and strong opioids were
used frequently for treating neuropathic pain, either alone or in
combination with other drugs (Hall 2013). The lack of evidence
for long-term benefit with fentanyl reflects similar findings for
oxycodone, buprenorphine, and other opioids (Gaskell 2014;
McNicol 2013; Wiffen 2015). This lack of evidence of efficacy
combined with substantial evidence of harm has led to calls for
referral to a pain management specialist (ideally with expertise
in opioid use) if daily dosing exceeds 80 to 100 mg morphine
equivalents, particularly if pain and function are not substantially
improved (Franklin 2014).
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The number of participants in the single included study (258
screened, 163 in the randomised double-blind phase) contrasts
with 1096 who participated in randomised open studies and 1393
in observational studies of various designs (Appendix 8). Despite
there being 2489 participants in these studies, with chronic pain of
mostly mixed origins, no useful conclusions can be drawn because
of problems in design, in outcomes, and in comparators used.
Although some people had useful pain relief with fentanyl, there
is no additional evidence that the proportion would be any higher
than with no treatment.
One study did provide a useful insight into the relative efficacy
of transdermal fentanyl and oral pregabalin in neuropathic cancer
pain (Raptis 2014). The study had a randomised but open parallel
design and was conducted over four weeks with initial titration for
both drugs; initial pain relief was high, about 7/10 on a numeri-
cal rating scale. Of 60 participants given transdermal fentanyl, 22
(37%) had pain intensity reduction of 30% or more. Of 60 par-
ticipants given oral pregabalin, 44 (73%) had that degree of pain
reduction. All-cause withdrawals were 10/60 for fentanyl and 3/
60 for pregabalin. Pregabalin has a well-established evidence base
in neuropathic pain (Moore 2009), and the evidence from this
open, but otherwise well-conducted study, indicates fentanyl to
be much less effective.
Quality of the evidence
Themethods used in the included study are fundamentally sound,
but the study is substantially underpowered, particularly for the
randomised, double-blind, withdrawal phase, and does not specify
the imputation method(s) used for withdrawals (Moore 2015). It
does not report the most useful outcome from the double-blind
phase, the number of participants who maintained therapeutic
efficacy and were able to continue taking the medication (with
tolerable adverse events), although we were able to estimate this.
These factors downgrade the evidence for all outcomes to very low
quality, which means that further research is very likely to have an
important impact on our confidence in our understanding of the
effect.
Potential biases in the review process
We know of no potential biases in the review process. It is unlikely
that there is a large body of unpublished evidence showing a large
effect from fentanyl in neuropathic pain.
Agreements and disagreements with other
studies or reviews
This review agrees with previous reviews and Cochrane reviews
that there appears to be no body of good clinical studies assess-
ing the efficacy of fentanyl, at any dose or in formulation, for
neuropathic pain (McNicol 2013). The one study in this review
was published after McNicol 2013. A recent review of all pharma-
cotherapy for neuropathic pain in adults did not mention fentanyl
(Finnerup 2015).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For people with neuropathic pain
There is insufficient evidence to support or refute the suggestion
that fentanyl has any efficacy in any neuropathic pain condition.
For clinicians
There is insufficient evidence to support or refute the suggestion
that fentanyl has any efficacy in any neuropathic pain condition.
For policy makers
There is insufficient evidence to support or refute the suggestion
that fentanyl has any efficacy in any neuropathic pain condition.
In the absence of any supporting evidence, it should probably not
be recommended, except at the discretion of a pain specialist with
particular expertise in opioid use.
For funders
There is insufficient evidence to support or refute the suggestion
that fentanyl has any efficacy in any neuropathic pain condition.
In the absence of any supporting evidence, it should probably not
be recommended, except at the discretion of a pain specialist with
particular expertise in opioid use.
Implications for research
Large, robust, randomised trials with patient-centred outcomes
would be required to produce evidence to support or refute the
efficacy of fentanyl in neuropathic pain. The necessary design of
such trials is well established, but, for opioids in neuropathic pain,
the main outcomes should be those of at least a 30% and at least a
50% reduction in pain intensity over baseline at the end of a trial
of 12 weeks’ duration in participants continuing on treatment.
Withdrawal for any reason should be regarded as treatment failure,
and LOCF analysis should not be used. The reason for this is that,
in chronic pain, opioids frequently produce withdrawal rates of
50%ormore,meaning that LOCFanalysis can overstate treatment
efficacy to a large extent. BOCF should be used in preference to
LOCF as it provides a more relevant estimate of efficacy for the
real world.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arai 2015
Methods Study N02. Multicentre, EERW, open-label titration phase (10 to 29 days), and parallel
group, double-blind withdrawal phase (12 weeks)
Participants PHN, CRPS, postoperative pain syndrome > 12 weeks, mean PI > 50/100, opioid-naïve,
inadequate PR with non-opioid analgesics
Excluded: pain from other causes, asthma, bradyarrythmia, severe respiratory function
disorders, hepatic dysfunction, renal impairment, hypersensitivity to fentanyl or other
opioids
N = 258 (titration phase)
M 134, F 124
Mean age 67 years (SD 14)
Mean baseline PI 74/100 (SD 13)
N = 163 (double-blind phase)
M 83, F 80
Mean age 67 years (SD 14)
Mean baseline PI 29/100 (SD 11)
Interventions Titration phase: fentanyl 1-day adhesive patch 12.5 µg/h for minimum 2 days. Increased
by 12.5 µg/h based on VAS PI and use of rescue medication to maximum 50 µg/h, over
10 to 29 days
Double-blind phase:
Fentanyl 1-day adhesive patch 12.5 to 50 µg/h, n = 84
Placebo patch, n = 79
Patches applied to chest abdomen, upper arm or thigh, replaced every day for 12 weeks
Rescue medication: morphine hydrochloride (5 mg per fentanyl 12.5 µg/h)
Outcomes Participants responding during titration period
Median time to withdrawal due to loss of analgesic efficacy
Median change in PI from randomisation to last 3 days of double-blind period (VAS)
Satisfaction scores
Notes Oxford Quality Score: R1, DB2, W1
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation not de-
scribed
Allocation concealment (selection bias) Unclear risk Not described
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Arai 2015 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Placebopatch indistinguishable fromone-
day adhesive transdermal patch containing
fentanyl”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Placebopatch indistinguishable fromone-
day adhesive transdermal patch containing
fentanyl”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Analyses used full analysis set, but no men-
tion of imputation methods. Study’s pri-
mary outcome seems robust, but other out-
comes unclear
Size Unclear risk 50 to 199 participants per treatment arm
CRPS: complex regional pain syndrome; DB: double-blind; EERW: enriched enrolment randomised withdrawal; F: female; M: male;
N: number of participants in study; n: number of participants in treatment arm; PHN: postherpetic neuralgia; PI: pain intensity;
PR: pain relief; R: randomised; SD: standard deviation; VAS: visual analogue scale; W: withdrawals.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Canneti 2013 Open-label study
Ding 2014 Compares fentanyl with fentanyl + gabapentin
Kalso 2007 Open-label, mixed conditions, secondary analysis of Allan 2005
NCT01127100 Single-blind (outcomes assessor), ongoing study
Park 2010 Open-label cohort, mixed conditions
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D A T A A N D A N A L Y S E S
This review has no analyses.
WH A T ’ S N E W
Last assessed as up-to-date: 14 June 2016.
Date Event Description
11 October 2017 Review declared as stable See Published notes.
C O N T R I B U T I O N S O F A U T H O R S
SD and RAM wrote the protocol.
SD and PC searched for and selected studies for inclusion and carried out data extraction.
All review authors were involved in the analysis and in writing the full review.
D E C L A R A T I O N S O F I N T E R E S T
SD: none known.
CS: none known. She is a specialist pain physician and manages patients with chronic pain.
PC received support from Boston Scientific (2014) for travel and accommodation at a scientific meeting; Boston Scientific does not
market drugs. PC is a specialist pain physician and manages patients with chronic pain.
PW: none known.
RK has consulted for Grunenthal Ltd (2014-15) and MundiPharma Research (2015), and received lecture fees from Grunenthal Ltd
(2013-14) and Pfizer Ltd (2013-14). He is an Associate Professor in Clinical Pharmacy Practice and Advanced Pharmacy Practitioner.
DA has received lecture fees from Grünenthal (2013, 2014, 2015) and Pfizer (2013, 2016). He is a specialist pain physician and
manages patients with chronic pain.
RAM has received grant support from RB relating to individual patient-level analyses of trial data on ibuprofen in acute pain and the
effects of food on drug absorption of analgesics (2013), and from Grünenthal relating to individual patient-level analyses of trial data
regarding tapentadol in osteoarthritis and back pain (2015). He has received honoraria for attending boards with Menarini concerning
methods of analgesic trial design (2014), with Novartis about the design of network meta-analyses (2014), and RB on understanding
the pharmacokinetics of drug uptake (2015).
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S O U R C E S O F S U P P O R T
Internal sources
• Oxford Pain Relief Trust, UK.
General institutional support
External sources
• The National Institute for Health Research (NIHR), UK.
NIHR Cochrane Programme Grant: 13/89/29 - Addressing the unmet need of chronic pain: providing the evidence for treatments of
pain
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol the inclusion criteria included both CRPS types I and II as a diagnosis of neuropathic pain. We have now removed
CRPS type I because it is no longer considered to be neuropathic pain. We identified no studies in CRPS type I.
N O T E S
No new studies likely to change the conclusions are expected. Therefore, this review has now been stabilised following discussion with
the authors and editors. If appropriate, we will update the review if new evidence likely to change the conclusions is published, or if
standards change substantially which necessitate major revisions.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Analgesics, Opioid [∗therapeutic use]; Fentanyl [∗therapeutic use]; Neuralgia [∗drug therapy]; Pain Measurement; Randomized Con-
trolled Trials as Topic
MeSH check words
Aged; Female; Humans; Male
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